9 recruiting, 6 completed, 3 terminated, 2 unknown. 8 Not applicable, 8 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 8 | Completed 3, Recruiting 2, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 8 | Recruiting 6, Unknown 1, Withdrawn 1 |
| Phase 1 | 5 | Completed 2, Recruiting 2, Terminated 1 |
Follow Yttrium-90: new trials by email Literature Review of Yttrium-90 trials Research Report on Yttrium-90
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma Yttrium-90, HAIC - Hepatocellular Carcinoma (HCC) | Not applicable | Recruiting | Li Qiang | 286 | 2026-08-01 | 2025-08-27 |
| A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC Yttrium [90Y] Microsphere Injection, Conventional transcatheter arterial chemoembolization, Camrelizumab - HCC | Phase 2 | Recruiting | GrandPharma (China) Co., Ltd. | 120 | 2025-08-22 | 2026-01-12 |
| SIRT Versus cTACE for Unresectable HCC (CHANCE2506) SIRT, cTACE - Unresectable Hepatocellular Carcinoma | Not applicable | Recruiting | Zhongda Hospital | 108 | 2025-04-03 | 2025-04-09 |
| Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant Atezolizumab & Bevacizumab, Yttrium-90 (Y-90), Stereotactic body radiotherapy (SBRT) - Hepatocellular Carcinoma (HCC), Macrovascular Invasion | Phase 1 / Phase 2 | Recruiting | University Health Network, Toronto | 48 | 2024-12-01 | 2024-12-16 |
| Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy radioembolization with Y-90, Durvalumab, Cisplatin - Intrahepatic Cholangiocarcinoma | Phase 2 | Recruiting | Francesco De Cobelli | 33 | 2024-04-30 | 2026-09-21 |
| Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio Gemcitabine, Cisplatin, Durvalumab - Bile Duct Cancer, Cholangiocarcinoma | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 30 | 2024-02-13 | 2026-04-22 |
| Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk Y90 + Atezolizumab and Bevacizumab, Y90 + TKI - Hepatocellular Carcinoma | Phase 2 | Recruiting | Northwestern University | 200 | 2022-11-30 | 2026-05-26 |
| Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases Yttrium-90 (Y-90) resin microspheres - Metastases | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 50 | 2022-11-16 | 2026-05-26 |
| CapTemY90 for Grade 2/3 NET Liver Metastases Capecitabine Oral Product, Temozolomide Oral Product, transarterial radioembolization - Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors | Phase 2 | Recruiting | Abramson Cancer Center at Penn Medicine | 70 | 2021-10-07 | 2026-10-08 |
| Assessment of the Efficacy of Stereotactic Intracavitary Instillation of 90Yttrium Colloid Yttrium90 - Neuroepithelial Cyst | Not applicable | Completed | David Clarke | 1 | 2021-03-23 | 2022-01-28 |
| Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Durvalumab, Yttrium-90 RadioEmbolization - Colorectal Cancer Metastatic, Colon Cancer | Phase 1 | Terminated | University of Iowa | 5 | 2020-10-05 | 2025-03-28 |
| Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging for Hepatic Malignancies PET/CT, PET/MR, SIRT with Y-90 - Hepatic Malignancies | Not applicable | Completed | Case Comprehensive Cancer Center | 11 | 2020-03-03 | 2022-06-22 |
| Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System Yttrium-90 - Hepatocellular Carcinoma, Secondary Malignant Neoplasm of Liver | Not applicable | Terminated | University of Minnesota | 14 | 2018-08-09 | 2025-03-24 |
| Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2) Lutetium-177 (177Lu)-DOTATOC, Yttrium-90 (90Y)-DOTATOC, 177Lu-DOTATOC + 90Y-DOTATOC - Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy (PRRT) | Not applicable | Unknown | University Hospital of Ferrara | 250 | 2018-07-02 | 2021-03-10 |
| Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization Perflutren Lipid Microspheres, Sulfur Hexafluoride Lipid Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging - Hepatocellular Carcinoma | Not applicable | Withdrawn | University of Southern California | 2017-11-07 | 2019-05-16 | |
| Prospective Tumor Response Evaluation TACE, Y-90, MWA - Hepatocellular Cancer, Metastatic Liver Cancer | Terminated | The University of Texas Health Science Center, Houston | 10 | 2016-01-01 | 2018-10-18 | |
| Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma TACE, radioembolization with Y-90 - Hepatocellular Carcinoma, Radioembolization | Not applicable | Completed | Eastern Hepatobiliary Surgery Hospital | 200 | 2012-12-01 | 2016-03-31 |
| Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver SIR-spheres Agent Administration, Cetuximab, Irinotecan - Colon Cancer, Colorectal Cancer | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2009-10-01 | 2013-01-03 | |
| Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma Sorafenib, Yttrium-90 (Y-90) - Hepatocellular Carcinoma | Phase 1 | Completed | Northwestern University | 24 | 2009-02-01 | 2016-09-15 |
| TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma TheraSphere - Hepatocellular Carcinoma | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 474 | 2007-10-01 | 2025-04-29 |
Showing 20 of 22. Sign in to see all of them.
Carcinoma, Hepatocellular (8) · Cholangiocarcinoma (2) · Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Liver Neoplasms (2) · Neoplasm Metastasis (2) · Neuroendocrine Tumors (2) · Bile Duct Neoplasms (1) · Carcinoma, Ovarian Epithelial (1) · Colloid cysts of third ventricle (1) · Ovarian Neoplasms (1) · Rectal Neoplasms (1) · Recurrence (1) · Sarcoma (1)
M.D. Anderson Cancer Center (2) · Northwestern University (2) · Abramson Cancer Center at Penn Medicine (1) · Beth Israel Deaconess Medical Center (1) · Case Comprehensive Cancer Center (1) · David Clarke (1) · Eastern Hepatobiliary Surgery Hospital (1) · Francesco De Cobelli (1) · GrandPharma (China) Co., Ltd. (1) · Li Qiang (1) · Ludwig Institute for Cancer Research (1) · Rocky Mountain Cancer Centers (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · The University of Texas Health Science Center, Houston (1) · University Health Network, Toronto (1)
United States (13) · China (4) · Canada (2) · Italy (2)
Andrea Bullock, MD, MPH (1) · Aparna Kalyan, MD (1) · Chaitanya R. Divgi, MD (1) · Chandrikha Chandrasekharan, MD (1) · Ching-Wei Tzeng, MD (1) · Colette Shaw, MD (1) · Dennise Carter, MD (1) · Derek L West, MD (1) · Gao-Jun Teng (1) · Gonzalo Sapisochin, MD, PhD, MSc (1) · Harshawn Malhi, MD (1) · Laura Kulik, MD (1) · Michael Soulen (1) · Ram Gurajala, MD (1) · Ravi Murthy, MD (1)
2016 (1), P30CA014089 (1), P30CA060553 (1)